ACADIA Pharmaceuticals, Inc
Acadia Pharmaceuticals is dedicated to advancing breakthroughs in neuroscience to elevate life. With over 30 years of experience, they have developed and commercialized the first and only FDA-approved treatments for hallucinations and delusions in Parkinson’s disease psychosis and Rett syndrome. Their clinical-stage efforts focus on addressing unmet needs in neuropsychiatric and neuro-rare diseases, including Prader-Willi syndrome and Alzheimer’s disease psychosis.
Industries
Nr. of Employees
large (251-1000)
ACADIA Pharmaceuticals, Inc
12830 El Camino Real, Suite 400, San Diego, CA 92130
Patents
Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
US-11840515-B2
View DetailsNeuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
US-11613515-B2
View DetailsNeuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
US-11603348-B2
View Details
Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
US-11840515-B2
View DetailsNeuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
US-11613515-B2
View DetailsNeuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
US-11603348-B2
View DetailsProducts
Regulatory-approved CNS therapies
Approved therapies for treating hallucinations and delusions in Parkinson’s disease psychosis and for treatment of Rett syndrome (product names removed).
Clinical-stage therapeutic pipeline for CNS disorders
Clinical-stage development programs focused on Alzheimer’s disease psychosis, Prader-Willi syndrome and other programs targeting neuropsychiatric symptoms in CNS disorders.
Regulatory-approved CNS therapies
Approved therapies for treating hallucinations and delusions in Parkinson’s disease psychosis and for treatment of Rett syndrome (product names removed).
Clinical-stage therapeutic pipeline for CNS disorders
Clinical-stage development programs focused on Alzheimer’s disease psychosis, Prader-Willi syndrome and other programs targeting neuropsychiatric symptoms in CNS disorders.
Services
Responds to unsolicited medical inquiries from licensed U.S. healthcare professionals with documented medical information and access to prescribing information and supporting documents.
Field-based expert engagement for scientific exchange and support of clinical questions related to therapies.
Information and support for external investigators seeking to conduct investigator-initiated studies related to company therapies.
Funding programs for independent medical education initiatives to improve disease awareness and patient care.
Patient-facing resources including support groups, educational content, and information about clinical trials and access programs.
Preparation and distribution of peer-reviewed manuscripts and conference materials to communicate clinical and scientific findings.
Responds to unsolicited medical inquiries from licensed U.S. healthcare professionals with documented medical information and access to prescribing information and supporting documents.
Field-based expert engagement for scientific exchange and support of clinical questions related to therapies.
Information and support for external investigators seeking to conduct investigator-initiated studies related to company therapies.
Funding programs for independent medical education initiatives to improve disease awareness and patient care.
Patient-facing resources including support groups, educational content, and information about clinical trials and access programs.
Preparation and distribution of peer-reviewed manuscripts and conference materials to communicate clinical and scientific findings.
Expertise Areas
- Clinical trial management
- Medical affairs and medical information
- Regulatory compliance and pharmacovigilance
- Neuroscience therapeutics (CNS disorders)
Key Technologies
- Clinical trial operations
- Pharmacovigilance and adverse event reporting systems
- Regulatory submission and labeling processes
- Medical affairs/MSL field engagement
News & Updates
Women have made remarkable contributions to healthcare and science. Learn how Acadia is empowering women in leadership.
Exploring innovative approaches in neuropsychiatric and neuro-rare diseases.
A collaboration to increase awareness of Parkinson’s disease psychosis.
Women have made remarkable contributions to healthcare and science. Learn how Acadia is empowering women in leadership.
Exploring innovative approaches in neuropsychiatric and neuro-rare diseases.
A collaboration to increase awareness of Parkinson’s disease psychosis.